-
Dabigatran Etexilate: Translational Thrombin Insight
2026-09-19
A mechanistic and strategic guide to using Dabigatran etexilate as a direct thrombin inhibitor in coagulation, atrial fibrillation, and translational research.
-
Sodium Salicylate as an NF-κB Inhibitor
2026-09-18
Sodium salicylate is a research-grade NF-κB inhibitor used to study inflammatory signaling and downstream oxidative-stress phenotypes. Its defined formula, solvent-specific solubility, refrigerated storage specification, and research-only status support controlled assay design, but the compound has not been validated as the active agent in the cited pancreatic nanomedicine study.
-
Ibrutinib, CSK Inhibition, and Atrial Fibrillation
2026-09-18
This study identifies inhibition of C-terminal Src kinase (CSK), rather than Bruton tyrosine kinase (BTK) blockade itself, as the strongest mechanistic explanation for ibrutinib-associated atrial fibrillation. By combining mouse electrophysiology, chemoproteomics, genetic models, pharmacology, and pharmacovigilance, the authors connect off-target kinase activity with electrical, structural, and inflammatory remodeling.
-
HATU Workflows for Peptide Coupling and Inhibitor Design
2026-09-17
HATU combines rapid carboxylic acid activation with practical amide and ester formation, making it useful for peptide synthesis chemistry and medicinal chemistry libraries. This guide connects a controlled HATU workflow with the structure-guided inhibitor strategy reported for IRAP and ERAP enzymes, including assay-ready purification and troubleshooting.
-
R1078 OX40L mRNA: Assay Design Insights
2026-09-17
EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) supports a layered approach to studying OX40L-mediated immune co-stimulation. This article translates mRNA dendritic-cell evidence into practical controls for expression, ligand display, receptor engagement, and T-cell function without overstating clinical relevance.
-
Cell lysis buffer for WB and IP: CAF workflow
2026-09-16
Build a reproducible workflow for protein extraction, Western blotting, and co-immunoprecipitation in cancer-associated fibroblast studies. This guide shows how a non-denaturing formulation supports ANGPTL4–IQGAP1 pathway analysis while preserving phosphoproteins and native protein interactions.
-
TCEP Hydrochloride for Protein Workflow Optimization
2026-09-16
TCEP hydrochloride provides odorless, water-compatible disulfide reduction for protein digestion, structural analysis, and redox assays. This practical guide connects reduction chemistry with SPRTN–DNA-protein crosslink research while showing where TCEP helps, where it can interfere, and how to optimize each workflow.
-
Sulfo-Cy3 NHS Ester for Vascular Labeling
2026-09-15
Sulfo-Cy3 NHS Ester combines aqueous compatibility with bright red fluorescence for protein and peptide workflows involving difficult-to-solubilize targets. Its NHS chemistry supports mechanistic assays of the AIBP–LRP2–HDL axis, uptake, binding, and endothelial remodeling without requiring organic co-solvents.
-
Tunicamycin: A Strategic Probe of ER Stress
2026-09-15
Tunicamycin is more than a conventional stress reagent: it is a mechanistically defined N-glycosylation inhibitor that can connect protein quality control, UPR signaling, macrophage inflammation, and disease-model translation. This article outlines how to use it as a strategic benchmark while avoiding overinterpretation of broad glycosylation blockade.
-
Phosbind Acrylamide for ISR Phosphoprotein Assays
2026-09-14
Phosbind Acrylamide converts phosphorylation-dependent mobility changes into an antibody-independent readout for pathway studies, kinase assays, and ISR experiments. This practical guide covers paired-gel design, MnCl2 optimization, coronavirus-related use cases, and troubleshooting for reproducible SDS-PAGE phosphorylation detection.
-
Covalent HPV16 E6 Inhibitors Restore p53 in Tumors
2026-09-13
The reference study identifies a genotype-defined vulnerability in HPV16 by covalently and irreversibly disabling the viral E6 oncoprotein near its E6AP-binding interface. E6 inhibition restored p53 activity, induced apoptosis and senescence, and suppressed established cervical and oropharyngeal tumor xenografts with limited toxicity, supporting a mechanism-led strategy for HPV-associated cancer treatment.
-
6-Thioguanine and EV71: BIRC3–Autophagy Mechanism
2026-09-12
The 2025 BMC Microbiology study identifies 6-thioguanine as an in vitro inhibitor of EV71 replication and links this activity to reduced BIRC3 expression and attenuation of complete autophagy. Its strong selectivity in HT-29 cells supports further antiviral investigation, while the cell-based design and mechanistic scope require validation in additional models and in vivo systems.
-
Aclacinomycin A for rDNA Damage Workflows
2026-09-11
Aclacinomycin A, or Aclarubicin, provides a practical model for connecting topological stress with persistent DNA lesions, nucleolar remodeling, and apoptosis. This guide translates the reference study into reproducible dosing, imaging, and troubleshooting workflows while keeping rDNA-specific effects distinct from generalized cytotoxicity.
-
Entecavir (BMS200475) HBV Research Workflow
2026-09-11
Build a reproducible Entecavir workflow around dose-response profiling, resistant HBV models, and orthogonal viral-DNA readouts. This guide connects practical cell-based assay design with translational interpretation while separating experimental recommendations from clinical evidence.
-
Rocket-Like Nanomedicine Restores PDAC Stroma
2026-09-10
Fu et al. developed an acid-responsive, multistage nanomedicine that remodels pancreatic ductal adenocarcinoma stroma before releasing gemcitabine from a mesoporous silica core. In a PDAC mouse model, this sequence produced marked tumor regression without evident treatment-related side effects, supporting stromal homeostasis restoration as an alternative to broad stromal ablation.